Last reviewed · How we verify
Ly-Cov016 (ETESEVIMAB)
Ly-Cov016 (Etesevimab) is a small molecule developed by Eli Lilly and Company, approved by the FDA in 2020 for the treatment of COVID-19. It is a monoclonal antibody that targets the SARS-CoV-2 virus, preventing it from entering host cells. Etesevimab is patented and commercially available, with no generic manufacturers listed. Key safety considerations include potential allergic reactions and infusion-related side effects. As a monoclonal antibody, it is designed to provide targeted therapy.
At a glance
| Generic name | ETESEVIMAB |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Monoclonal antibody |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
- COVID-19
Common side effects
Key clinical trials
- Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
- COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (PHASE2,PHASE3)
- A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19 (PHASE1)
- UPMC OPTIMISE-C19 Trial, a COVID-19 Study (PHASE4)
- Non-inferiority Trial on Monoclonal Antibodies in COVID-19 (PHASE3)
- A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ly-Cov016 CI brief — competitive landscape report
- Ly-Cov016 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI